Results indicate that TBX6 is aberrantly reactivated in CRC and promotes tumor progression through transcriptional network remodeling, suggesting that TBX6 may represent a potential prognostic biomarker and therapeutic target.
Abstract
The role of T-box transcription factor 6 (TBX6), a developmental transcription factor, in tumor initiation and progression in colorectal cancer (CRC) remains unclear. The present study investigated the expression pattern, biological functions, and downstream transcriptional regulatory networks of TBX6 in CRC. Public databases, clinical cohorts, functional assays, xenograft models, and RNA sequencing coupled with Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and protein-protein interaction analyses were used to define TBX6-associated molecular alterations. TBX6 was markedly upregulated in CRC tissues and cell lines, and its high expression was associated with advanced stage, lymph node metastasis, and poor survival. Functionally, TBX6 promoted proliferation, migration, invasion, and epithelial-mesenchymal transition in CRC cells in vitro, whereas TBX6 knockdown suppressed these malignant phenotypes and inhibited tumor growth with reduced proliferation and increased apoptosis in vivo. Transcriptomic analyses showed that TBX6 knockdown induced coordinated gene expression reprogramming and altered multiple tumor-related pathways. Protein-protein interaction analysis identified C-X-C motif chemokine ligand 14 (CXCL14), NOTUM, adrenoceptor α2A (ADRA2A), and melanin-concentrating hormone receptor 1 (MCHR1) as hub nodes within the TBX6-regulated network. Mechanistically, TBX6 knockdown regulated CXCL14 expression and attenuated Wnt/β-catenin signaling, findings that were further validated in xenograft tissues. These results indicate that TBX6 is aberrantly reactivated in CRC and promotes tumor progression through transcriptional network remodeling, suggesting that TBX6 may represent a potential prognostic biomarker and therapeutic target.
Both in vitro assays and in vivo models confirmed that silencing ZNF695 dramatically suppresses CRC cell proliferation, migration, and invasion, while concurrently impeding tumor progression.
Xiaozhun Tang, H. Ke, Ying Huang· Molecular Carcinogenesis· 0 citations
Integrative analysis identifies VIM, SNAI1, ZEB1, and FN1 as a candidate EMT-associated hub signature linked with NPC progression, prognosis, and drug response patterns, suggesting that this EMT hub network may have potential value as a prognostic biomarker panel and as a putative therapeutic vulnerability requiring fu...
Xiao-Peng Sun, Bo Kou· Naunyn-Schmiedeberg's Archiv...· 0 citations
Elevated TPD52 expression was associated with longer overall survival in specific subgroups, including the basal-like subtype, invasive lobular carcinoma, and N0/N1 stages, and a random forest-based diagnostic model demonstrated high accuracy across multiple datasets.
J. Yu, Z. Zhu, R. Deng et al.· medRxiv· 0 citations
Findings identify NTMT1 as a candidate regulatory node associated with MYC activation and downstream HLA-A suppression, warranting further mechanistic and in-vivo investigation, and highlighting NTMT1 as a promising candidate for future therapeutic investigation.
Jin-Ling Zhang, Chen Chen, Huibin Song et al.· Frontiers in Immunology· 0 citations
Cadherin genes, particularly CDH3, show diagnostic and prognostic relevance in HNSC, while CDH1 and CDH2 contribute to tumor cell growth and migration.
Mostafa A. Abdel-Maksoud, Abdulaziz Alamri, Aljawharah Fahad et al.· World Journal of Surgical On...· 0 citations
This study aimed to investigate the biological function, clinical significance, and underlying molecular mechanism of the RNA‐binding protein YTHDF3 in gastric cancer (GC) progression.
Xiaoran Sun, Yi-Fan Chen, Kun-Yi Liu et al.· Journal of Gastroenterology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.